Skip Navigation


Briefings in Functional Genomics and Proteomics Advance Access originally published online on April 7, 2009
Briefings in Functional Genomics and Proteomics 2009 8(2):158-166; doi:10.1093/bfgp/elp006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
8/2/158    most recent
elp006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Gao, Y.
Right arrow Articles by Yu, L.-R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gao, Y.
Right arrow Articles by Yu, L.-R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press. For permissions, please email: journals.permissions@oxfordjournals.org

This article appears in the following Briefings in Functional Genomics and Proteomics issue: Special Issue: Target Quantitative Proteomics: The Next Logical Step in Proteomics [View the issue table of contents]

Special Issue Papers

Quantitative proteomics for drug toxicity

Yuan Gao, Ricky D. Holland and Li-Rong Yu

Corresponding author. Li-Rong Yu, PhD, Center for Proteomics, Division of Systems Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, 3900 NCTR Rd, HFT-233, Jefferson, AR 72079, USA. Tel: +1-870-543-7052, Fax: +1-870-543-7686; E-mail: lirong.yu{at}fda.hhs.gov

The emerging field of toxicoproteomics has been greatly advanced by quantitative proteomic technologies and their increasing applications in toxicology. The discipline is focused on the proteomic study of toxicity caused by toxic substances, including but not limited to drugs, toxins, environmental stressors, chemicals and any other materials that induce significant pathological responses. Drug safety is a major point of concern during the development phase and clinical application. Identification of toxicity biomarkers, potential drug targets and characterization of toxicity mechanisms represent major research areas for quantitative toxicoproteomics during drug development and evaluation. Further development and application of quantitative proteomic approaches would significantly facilitate the realization of personalized medicine.

Keywords: proteomics, mass spectrometry, toxicity biomarker, drug target, toxicity mechanism, toxicoproteomics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.